Let’s start working together, today. You can contact us!
NBLST
Latest Updates
March 06, 2026
MWX401 Injection Granted IND Approval: siRNA + Nanobody, Reshaping a New Paradigm for Long-Acting Hypertension Treatment
In March 2026, the Chinese innovative drug sector received exciting news — MWX401 Injection, an independently developed small interfering RNA (siRNA) novel drug, was officially issued the Clinical...
March 06, 2026
February 07, 2026
A Disruptive Breakthrough: Intranasal Delivery of Nanobodies Opens a New Pathway for Depression Treatment
A recent international collaborative research team published a landmark study in the top-tier journal Nature Communications. For the first time, they successfully developed a nanobody (Nb20)...
February 07, 2026
January 30, 2026
In-depth Analysis of PD-L1 Target: Why It Has Become a "Star Target" in Cancer Immunotherapy?
In the golden track of cancer immunotherapy, immunotherapy targeting PD-1 (Programmed Death Receptor 1) has become a classic paradigm, but its single-target strategy faces bottlenecks in clinical...
January 30, 2026
Support is Online
We're back! We are here to assist you. Please be patient, we will respond to your tickets shortly.
Official support hours
Monday To Friday
From 9:00AM To 6:00PM
Address
Building A, 15th Floor, WHIIID Headquarters, No. 666 Gaoxin Avenue, East Lake New Technology Development Zone, Wuhan City, P.R of China
Call Us now
Email & Social